News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Anergis To Present New COP Allergy Vaccine Data At European Academy of Allergology and Clinical Immunology Conference 2014 In Copenhagen

5/27/2014 1:34:43 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

EPALINGES, Switzerland, May 27th, 2014 – Anergis, a company discovering and developing proprietary allergy vaccines, today announced it will present four scientific communications on its Contiguous Overlapping Peptides (COP) allergy vaccines at this year’s European Academy of Allergy and Clinical Immunology Congress 2014 (EAACI) in Copenhagen, Denmark. The presentations focus on Anergis´ lead compound AllerT against birch pollen allergies, its house dust mite vaccine candidate AllerDM, and a general economic evaluation of allergen immunotherapy for seasonal allergies. The following scientific communications will be presented at the EAACI Conference 2014:

Presentation Title: "AllerT™, Safety and efficacy of a birch pollen allergy vaccine based on contiguous overlapping peptides in a phase IIb study"
Presenter: Prof. Dr. Marek Jutel
Time and Date: Sunday, June 8, 2014, at 03:30pm CET
Session: Oral Abstract Session OAS12: Novel Vaccines for AIT
Abstract #: 481

Presentation Title: "Development of a hypoallergenic formulation for immunotherapy against house dust mite allergy based on Contiguous Overlapping Peptides"
Presenter: Dr. Alexander Kettner
Time and Date: Monday, June 9, 2014, at 03:45pm CET
Session: Poster Discussion Session PDS 12: AIT Mechanisms
Abstract #: 347

Presentation Title: "Effect of AllerT™ ultra-fast immunotherapy on Bet v 1 specific IgG4 and IgE levels; results from a phase IIb study"
Presenter: Prof. Dr. Christophe Reymond
Time and Date: Monday, June 9, 2014, at 03:45pm CET
Session: Poster Discussion Session PDS 12: AIT Mechanisms
Abstract #: 559

Presentation Title: "Economic evaluation of allergen immunotherapy for seasonal allergic rhinitis"
Presenter: Jean-Paul Rohmer
Time and Date: Tuesday, June 10, 2014, at 12:00pm CET
Session: Thematic Poster Session TPS64: Immunotherapy - AIT Clinics IV
Abstract #: 1411

About Anergis
Anergis SA is a Swiss-based biopharmaceutical company specializing in the discovery and development of novel, proprietary allergy vaccines that target commercially attractive indications. Anergis´ vaccines are based on its IP-protected Contiguous Overlapping Peptide (COP) technology. Allergies are the most prevalent and fastest growing chronic conditions in the industrialized world affecting over 500 million people.
Anergis’ lead-product AllerT, a vaccine to treat birch pollen allergies, is due to enter Phase III clinical development. Two additional vaccine candidates against ragweed pollen allergies (AllerR) and house dust mite allergies (AllerDM) are in preclinical development.
Anergis has raised over CHF 30 million from Renaissance PME/Vinci Capital, Sunstone Capital, BioMedInvest and other investors, including Esperante Ventures and Initiative Capital Romandie/Defi Gestion.

About Anergis´ Contiguous Overlapping Peptides (COP) Technology
The only curative therapy of allergies available today, known as “desensitization” or “Conventional Allergy Immunotherapy” (AIT), is the process of inducing tolerance to the allergen. It requires 3-5 years of treatment and exposes patients to the risk of serious side effects – in particular immediate (<30 min) anaphylactic reactions – which can be life-threatening. With its ultra-fast desensitization, Anergis is shaping the future of allergy treatment. Anergis’ vaccines are based on COPs which reproduce the complete amino acid sequence of the allergen in separate synthetic long peptides. COP allergy vaccines are pharmaceutical quality products that provide the complete allergen sequence covering all T cell epitopes, but do not cross-react with IgE, the antibody class responsible for eliciting allergic hypersensitivity. Therefore, COPs can be administered safely independent of MHC restriction and at high doses to induce tolerance to the allergen after only a few injections. This enables desensitization in 2 months as opposed to 3 years. Studies of COPs targeting bee venom and birch pollen allergies in both animals and humans have demonstrated excellent safety (i.e. no immediate allergic reaction) and immunogenicity (production of specific antibodies and cytokines against the original allergen and establishment of a long-term immune memory).

Anergis SA
CH-1066 Epalinges
Vincent Charlon, CEO

Media Inquiries:
Dr. Ludger Wess, Ines-Regina Buth
Managing Partners
Tel. +49 40 88165964 or +49 30 2363 2768

Help employers find you! Check out all the jobs and post your resume.

Read at

comments powered by Disqus